(MENAFN- Investor Brand Network)
Longeveron recently released its full-year results for the period ended December 31, 2023, and provided a corporate update The update outlined the company's plans to prioritize the development of Lomecel-B(TM) in Hypoplastic Left Heart Syndrome (“HLHS”), a rare, pediatric congenital heart condition characterized by an underdeveloped left side of the heart Longeveron plans to complete the enrollment in the ELPIS II trial for HLHS in 2024 The company also reported that it is exploring opportunities to advance its Alzheimer's disease program through potential partnerships or other sources of funding
Longeveron (NASDAQ: LGVN) , a clinical-stage biotechnology company developing regenerative medicine for life-threatening conditions with unmet medical needs, recently released its full-year results for the period ended December 31, 2023, and provided a corporate update ( ). Results from multiple studies using Longeveron's lead investigational therapeutic candidate, Lomecel-B(TM), were announced by the company last year.
“In 2023 we made significant strides advancing studies of our investigational product, Lomecel-B(TM), in Hypoplastic Left Heart Syndrome (“HLHS”) and Alzheimer's disease, with long-term survival data from ELPIS I trial presented at the American Heart Association ('AHA') annual meeting and clinically...
Read More>>
NOTE TO INVESTORS:
The latest news and updates relating to LGVN are available in the company's newsroom at
About BioMedWire
BioMedWire
(“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the
Dynamic Brand Portfolio
@
IBN
that delivers :
(1) access to a vast network of wire solutions via
InvestorWire
to efficiently and effectively reach a myriad of target markets, demographics and diverse industries ;
(2) article and
editorial syndication to 5,000+ outlets ;
(3) enhanced
press release enhancement
to ensure maximum impact ;
(4)
social media distribution
via IBN to millions of social media followers ;
and (5) a full array of tailored
corporate communications solutions . With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today's market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire,“Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published:
/Disclaimer
BioMedWire
San Francisco, CA
415.949.5050 Office
...
BioMedWire is powered by
IBN
MENAFN28032024000224011066ID1108035307
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.